What Happened?

Shares of vaccine biotechnology company Novavax (NASDAQ: NVAX) jumped 3% in the morning session after reports revealed that its JN.1 Covid-19 vaccine became available at some GP clinics in Singapore. 

This batch of the vaccine was made available from January 2 until May 31, 2026. The development occurred against a backdrop of cautious optimism in the biopharmaceutical sector for the year. A survey of industry professionals showed 52% felt optimistic about growth in 2026. This news followed the company's recently reported third-quarter 2025 financial results, which were mixed. Although Novavax beat revenue expectations with $70.45 million, sales had fallen 16.6% from the previous year, and the company's loss per share was wider than analysts had expected.

Is now the time to buy Novavax? Access our full analysis report here.

What Is The Market Telling Us

Novavax’s shares are extremely volatile and have had 47 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

Novavax is down 16.7% since the beginning of the year, and at $7.14 per share, it is trading 34.1% below its 52-week high of $10.82 from January 2025. Investors who bought $1,000 worth of Novavax’s shares 5 years ago would now be looking at an investment worth $63.15.

The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave.